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Introduction
Chronic obstructive pulmonary disease (COPD) 
is the third leading cause of death worldwide [1]. A 
significant part of the morbidity and mortality cases, 
and of the costs of COPD, is related to exacerbations. 
The most common causes of these exacerbations 
appear to be respiratory infections, of viral or bacterial 
origin [2]. However, differences in inflammatory status, 
level of hyperinflation, and anxiety contribute as well 
[3, 4]. The mainstream medical treatment consists 
of bronchodilators, which can be administered by 
nebulizers or inhalers, and corticosteroids [2]. The 
need for antibiotics is under continuous investigation 
and discussion [5]. There are many reasons to be 
restrictive with antibiotics, including increasing 
antibiotic resistance, their adverse effects, and the 
difficulty in distinguishing between bacterial infections 
and viral infections; if viral, antibiotics should not be 
administered [3].
This leads to an important clinical challenge: 
to quickly distinguish between viral, bacterial, and 
non-infectious causes of exacerbations. A bacterial 
culture of sputum is the most important diagnostic 
tool for bacterial infections; for viral pathogens serol-
ogy is commonly used, and more recently, PCR is 
applied in some hospitals. However, these techniques 
are time consuming, expensive and/or require an 
extensive infrastructure. So the search for improved 
screening tools to make important treatment deci-
sions continues. Preferably, these tools should sup-
port decisions that prevent in-hospital-spread of 
viruses as well [6]. Such a screening tool needs to be 
easy-to-use, patient friendly, quick, and preferably fit 
for point-of-care testing. It will be even more useful in 
settings with limited or no microbiological support.
An electronic nose, (e-nose) could become this 
new screening tool. An e-nose measures volatile 
organic compounds (VOCs). A large number of VOCs 
are present in exhaled breath. Electronic noses can be 
based on several different technological principles, 
e.g. sensor arrays consisting of conducting polymers, 
quartz-microbalance based sensors, nanomaterial-
based sensors, and colorimetric sensors [7, 8].
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Abstract
Respiratory infections, viral or bacterial, are a common cause of acute exacerbations of chronic 
obstructive pulmonary disease (AECOPD). A rapid, point-of-care, and easy-to-use tool 
distinguishing viral and bacterial from other causes would be valuable in routine clinical care. An 
electronic nose (e-nose) could fit this profile but has never been tested in this setting before. In a 
single-center registered trial (NTR 4601) patients admitted with AECOPD were tested with the 
Aeonose® electronic nose, and a diagnosis of viral or bacterial infection was obtained by bacterial 
culture on sputa and viral PCR on nose swabs. A neural network with leave-10%-out cross-validation 
was used to assess the e-nose data. Forty three patients were included. In the bacterial infection 
model, 22 positive cases were tested versus the negatives; and similarly 18 positive cases were tested 
in the viral infection model. The Aeonose was able to distinguish between COPD-subjects suffering 
from a viral infection and COPD patients without infection, showing an area under the curve (AUC) 
of 0.74. Similarly, for bacterial infections, an AUC of 0.72 was obtained. The Aeonose e-nose yields 
promising results in ‘smelling’ the presence or absence of a viral or bacterial respiratory infection 
during an acute exacerbation of COPD. Validation of these results using a new and large cohort is 
required before introduction into clinical practice.
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In the Aeonose®, metal-oxide sensors are used. 
Using this specific technology, it has been feasible to 
distinguish between tuberculosis infections and other 
lung diseases [9].
E-noses using other techniques have been capable 
of diagnosing bacterial sinusitis and ventilator-associ-
ated pneumonia [10, 11]. E-noses have been used to dis-
tinguish between asthma and COPD, and more recently 
in more advanced trials in profiling stable COPD and 
asthma [8, 12–14]. It is also possible to now identify 
whether or not patients are suffering from an exacerba-
tion of COPD [15].
So far, electronic noses have not been tested in the 
setting of acute exacerbations of COPD, especially not 
from the viewpoint of choosing treatment guided by 
possible etiologies of the exacerbation. In contrast to 
some other e-noses, the recently developed handheld 
Aeonose is easy-to-use, patient friendly, and quick. 
Collection bags are not required. Besides this, cali-
bration models can be transferred to other Aeonose 
devices removing the need to calibrate e-noses indi-
vidually [16]. This enables point-of-care testing, open-
ing up the possibility of a tool that could be used for 
daily practice in exacerbation treatment.
This trial was designed to assess the Aeonose 
for rapid, easy-to-use, patient friendly, discrimina-
tion between causes of exacerbations of COPD. The 
hypothesis tested is that using this e-nose, it is feasible 
to detect the presence of a viral or bacterial cause of 
acute exacerbations of COPD.
Methods
This trial was registered in the WHO approved 
International Clinical Trials Registry Platform, The 
Netherlands Trial Registry (NTR 4601).
The study was conducted in the emergency room 
and pulmonary ward of our university teaching hospi-
tal in Groningen (The Netherlands).
Subjects
Patients diagnosed with COPD by current GOLD 
standards were screened [2]. The main criteria used 
were postbronchodilator forced expiratory volume in 
one second  <80% predicted and postbronchodilator 
forced expiratory volume in one second/forced vital 
capacity  <0.70. All patients were former or current 
smokers.
Figure 1. The Aeonose in use.
Figure 2. Flowchart of patient inclusion.
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All were diagnosed with an acute exacerbation 
of COPD and hospitalized. The diagnosis was made 
based on the GOLD definition of an acute event char-
acterized by worsening of the patient’s respiratory 
symptoms that is beyond normal day-to-day varia-
tions and leads to a change in medication [2]. During 
the first days of their hospital stay, sputum cultures, 
a nose brush for PCR for viral respiratory infections, 
and exhaled breath analysis by Aeonose were obtained. 
Blood cultures were taken if deemed necessary by the 
treating physician.
Participants needed to fit the inclusion criteria: 
a diagnosis of COPD, a confirmed COPD exacerba-
tion, admission to the pulmonary ward, and a spu-
tum bacterial culture and nose swab for viruses. Sub-
jects were excluded if they suffered from lung cancer, 
respiratory insufficiency requiring ventilation, or if 
they could not adequately hold the Aeonose during 
the test themselves. Patients with a pneumonia con-
firmed by chest radiograph were excluded as well. 
Patients were treated during their admission with 
bronchodilators, corticosteroids, and supplemen-
tal oxygen. Besides this, most were also treated with 
antibiotics. All participants provided informed con-
sent before performing study procedures and after 
being informed on the purposes and details of the 
investigation. Based on earlier pilot studies for dif-
ferent indications with this e-nose, a sample size of 
40 subjects was chosen.
Primary endpoints
	•	 The	ability	to	ascertain	the	presence	of	a	
respiratory bacterial infection during an acute 
exacerbation of COPD by Aeonose.
	•	 The	ability	to	ascertain	the	presence	of	a	
respiratory viral infection during an acute 
exacerbation of COPD by Aeonose.
Decision rules
Decision rules were agreed upon and followed by the 
study team regarding the issue whether participants 
suffered from a bacterial, viral, or no respiratory tract 
infection.
The diagnosis of viral infection was established 
if the nose swab tested positive by polymerase chain 
reaction (PCR). Primers for the 15 most common res-
piratory viruses in The Netherlands were used. A viral 
infection was established to be negative if the test result 
was negative with a cutoff cycle threshold of 40. The 
diagnosis of bacterial infection was established if either 
the blood or sputum culture was positive for a bacte-
rial pathogen. A bacterial infection was established to 
be negative if the test result showed negative. Patients 
suffering from both bacterial and viral infections were 
allowed to be included.
Spontaneous sputum samples were cultured on 
sheep blood, chocolate, and MacConkey agar plates 
at 35 °C for 48 h in 5% CO2. A sputum culture was 
considered to be positive if the cultured microorgan-
isms are potentially pathogenic, the growth density in 
the culture is high (semi quantitative), the number of 
squamous epithelial cells is  <25, and the number of 
the leukocytes in the Gram-stained preparation of the 
sputum sample is  >15 per high power field (100  ×  10). 
This corresponds with the Geckler and Bathoorn group 
[17, 18].
The Aeonose
The Aeonose (The eNose Company, Zutphen, The 
Netherlands) is a handheld device (figure 1) using 
three metal-oxide sensors (AMS Premstaetten, 
Austria), which consist of different metals that allow 
for various interactions with volatile compounds. 
These include carbon monoxide (AS-MLC), nitrogen 
dioxide (AS-MLN), and volatile organic compound 
(AS-MLX) sensors. Exhaled air is guided over these 
sensors. At the sensor surfaces, redox reactions can 
occur. These reactions lead to conductivity changes that 
are measured. The sensors are exposed to a sinusoidal 
temperature cycle between 280 °C and 340 °C thus 
providing information on the temperature dependence 
of the redox reactions as the conductivity is measured 










N 43a 22 21 18 25
Sex F/M 18/25 8/14 10/11 10/8 8/17
Age 67  ±  11 66  ±  12 68  ±  11 66  ±  10 68  ±  12
Classification of severity of airflow by  
GOLD I/II/III/IV
2/18/13/10 1/8/6/7 1/10/7/3 2/6/7/3 0/12/6/7
Current smokers/ex-smokers/never smokers 20/23/0 10/12/0 10/11/0 10/8/0 10/15/0
Pack years 44  ±  21 43  ±  25 44  ±  19 45  ±  20 43  ±  20
Number of participants treated with systemic 
steroids before breath pattern measurement
37 19 18 18 19
Number of participants treated with  
antibiotics before breath pattern measurement
26 13 13 12 14
a Nine patients had both a bacterial and a viral respiratory tract infection, 12 patients had no infection. Results are shown as mean  ±  SD.
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32 times during each cycle. The temperature profile 
consists of two consecutive cycles lasting 20 s in total, 
thus resulting in 64 values every 20 s for each of the 
three sensors. This leads to a conductivity pattern for 
the VOCs present in the exhaled breath. In order to 
achieve data reproducibility, the temperature control 
of the sensors is within approximately 1 °C.
Patients are asked to breathe normally in and out 
through the device for 5 min. No collection bags are 
required so exhaled VOCs are analyzed in real-time.
During the first 2 min, no measurements are 
recorded and this period of time is used for clearing 
the lungs with filtered air. During the next three min-
utes, conductivity values of exhaled air are recorded. 
After these 5 min, the patient can stop breathing 
through the Aeonose, and the device starts regenerat-
ing the sensors by flushing with air. After this, a Tenax® 
tube is heated and VOCs released are guided over the 
sensors. Then the sensors are regenerated with air. In 
that way, a full measurement takes 15 min, and for 
12 min conductivity values are recorded. The dispos-
able mouthpieces are equipped with a HEPA-filter 
to provide hygiene. This mouthpiece also contains a 
carbon filter to ensure that the patient does not inhale 
volatiles that could disturb the measurement. A nose 
clamp is used to make sure the subject is breathing 
through the mouth.
The Aeonose weighs 650 g. Note that the Aeonose 
measures an integrated breath profile, not a specific 
VOC in the exhaled breath.
The main objective of this device is to classify the 
measured conductivity pattern of a subject. Therefore, 
it is necessary to train the Aeonose by exposing it to 
the breath of a series of well-diagnosed individuals 
according to the groups of the protocol. In that way, 
the Aeonose can learn to distinguish between groups. 
The methodology for achieving this is described in the 
next section.
Statistical analysis
As described in the literature, the evaluation of 
data from sensor arrays like the Aeonose contains 
several steps [7, 19]. This trial followed the steps of 
those articles, including data acquisition, data pre-
processing, data reduction, and training of an artificial 
neural network (ANN).
As conductivity values are recorded for 12 min as 
described above, each patient’s measurement com-
Figure 3. ROC curve of association between exhaled-breath patterns and viral infections during AECOPD.
Figure 4. ROC curve of association between exhaled breath patterns and bacterial infections during AECOPD.
J. Breath Res. 10 (2016) 036001
5W H van Geffen et al
prises of thousands of records. The temperature con-
trol described above enables proper reproducibility of 
the results. However, even for sensors produced on the 
same wafer, thickness and aging differences cause slight 
variations between sensors and Aeonoses over time. In 
order to cope with this phenomenon, the data were 
scaled, and multiple noses were used [16].
As the matrix size is too large for classification, and 
in order to avoid so-called voodoo-analyses, the data 
were scaled and then compressed using a Tucker3 solu-
tion [20, 21].This resulted in a vector of 11 components 
per patient.
The vectors generated in the study, combined with 
a classifier value (either bacterial or viral), were used 
to train a back-propagating artificial neural network 
(ANN) and investigate if the ANN would be able to 
distinguish between the two groups. In order to make 
sure that classification results are based on actual differ-
ences between subjects, and not on data coincidences 
or over-fitting of data, so-called leave-10%-out cross-
validation was applied.
In practice, this means that 10% of data is left out, 
and an ANN is trained using the remaining 90%. With 
the ANN model found, the remaining 10% of data is 
analyzed. In the next step, another 10% of data of the 
total dataset is left out, and the remaining 90% is used to 
train a second ANN followed by classifying 10% of data 
left out previously. This process is followed ten times, 
so all data are classified once based on training another 
part of the dataset. The results shown in the next sec-
tion are constructed from ten separate ANNs.
For this data analysis, proprietary software was 
used, developed in-house at The eNose Company.
Results
During the trial, 72 patients were screened. Based on 
the inclusion and exclusion criteria 25 patients were 
not eligible, largely due to patients’ inability to provide 
sputa for culture. Therefore, 47 patients were assessed. 
Four participants were excluded for technical reasons 
(see figure 2). So, 43 patients were included. Detailed 
baseline characteristics of the 43 patients are presented 
in table 1.
Viral infections
Data were analyzed using an ANN as described before, 
and a receiver operating curve (ROC) was created to 
assess the Aeonose performance for this indication. 
The group with a viral infection was tested versus the 
group without a viral infection. An area under the curve 
(AUC) of 0.74 was found. Based on the ROC curve, a 
sensitivity of 83% and a specificity of 72% can be 
achieved (figure 3).
Bacterial infections
Similarly, for bacterial infections, data were analyzed 
and a receiver operating curve (ROC) was created to 
assess the Aeonose performance. The group with a 
bacterial infection was tested versus the group without 
a bacterial infection. This model has an AUC of 0.72. A 
sensitivity of 0.73 and a specificity of 0.76 was can be 
achieved (figure 4).
Discussion
The electronic nose tested, the Aeonose, was able to 
detect the presence or absence of a viral or bacterial 
respiratory infection during an AECOPD with a 
promising accuracy.
To our knowledge, this is the first registered pro-
spective trial assessing the cause of AECOPD by e-nose 
technology. Like phenotyping stable COPD, the rec-
ognized importance of phenotyping exacerbations of 
COPD is growing as well [4, 22–24]. One of the most 
important differences between exacerbations may be 
the cause. Several phenotypes have been identified 
already [23, 25–27]. This trial shows the potential of 
the e-nose in phenotyping AECOPD.
Important treatment decisions in exacerbation treat-
ment are taken every day, and are usually only partially 
based on phenotypes. Important questions that arise 
daily include: are antibiotics required? Are antiviral treat-
ments required? Should this patient be isolated during 
hospital stay from other patients or sent home to prevent 
in-hospital-spread of viruses? Is the potential harm by 
drugs (antibiotics) outweighed by the expected benefit?
Current tools like viral serology, viral PCR and bac-
terial cultures have a classical role in answering these 
questions. However, these are not easily available, costly, 
and most importantly, test results become available 
with a considerable delay. It would be advantageous to 
not have to wait for 1–3 d for results to become avail-
able. One could assume that clinicians will be happy 
for day-to-day care with tools like the Aeonose when 
proven to work reliably and cost-effectively.
The Aeonose has additional advantages making it 
an even more interesting tool to fill the earlier described 
gap in exacerbation treatment: the Aeonose is easy-to-
use, no collection bags are required, and it is patient 
friendly because it can be used by the bedridden patient, 
and patients can maintain their regular breathing fre-
quency. Measurements are inexpensive and, as opposed 
to the current standard by culture or viral PCR, no 
microbiology department is needed.
Within the field of obstructive airways diseases, 
e-nose technology has already proven its use in distin-
guishing asthma from COPD, profiling stable disease, 
and finding exacerbations [14, 15]. These results, using 
an e-nose based on metal-oxide sensors, confirm ear-
lier studies for different infections for other diseases 
or circumstances [9, 28–31]. Several different sensor 
techniques were used in those earlier trials. It would 
be interesting to investigate whether these results are 
specific to the e-nose technique used, or can also be 
achieved with e-noses based on arrays of conducting 
polymers, quartz microbalance sensors, nanomaterial-
based sensors or colorimetric sensors.
J. Breath Res. 10 (2016) 036001
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The design of the pilot study has several limitations, 
of which sample size is one, leaving no possibility within 
the pilot to validate the results and to assess reproduc-
ibility in a second cohort. To address this, a leave-10%-
out cross-validation was performed. The next step is to 
perform a confirmation study in a large blinded cohort 
to assess accuracy of the prediction. This method prop-
agated by the STARD statement and recently by Bikov 
et al to assess e-nose technology, is probably the right 
way forward [7, 32]. Another future step is to test the 
system for detection of individual pathogens, which 
will require a much larger sample size.
In the Dutch health care system patients are often 
treated with antibiotics prior to referral to the hospital. 
Therefore, the use of antibiotics was registered thor-
oughly, but not excluded. Effects of antibiotics can be 
swift, especially in infections with S. pneumonia. This 
would have the effect of lowering the AUC, which was 
now 0.72. We had considered including only patients 
without prior antibiotics, but this would render the set-
ting less clinically relevant. Our reasoning was: when a 
patient with a COPD exacerbation visits the hospital 
and a decision needs to be made regarding the presence 
of infection, all-comers are the group of interest.
This trial is a first step towards a fast, patient 
friendly, point-of-care, and low-cost assessment of the 
cause of infections in AECOPD. Worldwide, assess-
ment of bacterial and viral infections is not performed 
in most practices and clinics due to financial and logisti-
cal limitations. When confirmed, these results would be 
a valuable tool. This could lead to decreased use of anti-
biotics and antiviral medication. This will have to be 
tested in further trials assessing treatment algorithms to 
adequately and personally target the administration as 
well as the withholding of antibiotics. Also, and perhaps 
increasingly important, a contribution could be made 
to rational and efficient patient isolation management 
to prevent in-hospital-spread of infections, especially 
viruses.
In summary, the e-nose tested, the Aeonose, holds 
promise as a quick point-of-care tool to assess the 
presence or absence of a viral or bacterial respiratory 
infection during AECOPD, and now needs to be con-
firmed.
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